Katharine A. Hodby

Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Journal: Haematologica
Published: August 01, 2026

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

Journal: Blood advances
Published: May 07, 2026

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Journal: Cancer research communications
Published: December 17, 2025

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Leukemia
Published: November 19, 2025

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Haematologica
Published: July 02, 2025

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.

Journal: The New England journal of medicine
Published: November 27, 2024

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.

Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.

Journal: Blood advances
Published: July 10, 2023

Bicytopenia and neurological defects caused by zinc toxicity.

Bicytopenia and neurological defects caused by zinc toxicity.

Journal: British journal of haematology
Published: March 11, 2022

Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Journal: Current treatment options in oncology
Published: February 26, 2020

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

Journal: Blood
Published: October 23, 2014

Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.

Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 01, 2013
Showing 1-11 of 11

Last Updated: 09/26/2026